Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer.
Gynecol Oncol
; 155(2): 186-191, 2019 11.
Article
in En
| MEDLINE
| ID: mdl-31519320
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Ovarian Neoplasms
/
Pyrimidines
/
Sulfonamides
/
Angiogenesis Inhibitors
/
Carcinoma, Ovarian Epithelial
Type of study:
Clinical_trials
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Middle aged
Language:
En
Journal:
Gynecol Oncol
Year:
2019
Type:
Article